Summit Therapeutics.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 28
What's happening
Earlier this month
One to three months ago
-
Summit Therapeutics is undergoing FDA review for a drug.Some support2 reports
-
Chinese biopharma is gaining ground, producing oncology drugs that rival established Western pharmaceuticals like those associated with Merck.Speculative1 report4 developments inside
-
Institutional investors bought and sold stock in Summit Therapeutics.Some support1 report
Gone quiet
No new reports in 90+ days-
Vertex Pharmaceuticals, Eli Lilly, and Summit Therapeutics are drugmakers with ongoing clinical trials.Some support1 report
-
Revolution Medicines and Summit Therapeutics announced a collaboration on August 19, 2025, to evaluate combination therapies.Some support3 reports1 development inside
-
Summit Therapeutics and AstraZeneca announced a partnership on July 4, 2025, to collaborate on lung cancer drug development.Speculative3 reports
-
Summit Therapeutics acquired an exclusive license from Akeso for developing bispecific assets, with ivonescimab showing strong results compared to Keytruda.Some support5 reports
-
Revolution Medicines and Summit Therapeutics are collaborating to evaluate combination therapies using RAS inhibitors and ivonescimab for targeted cancer treatment.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Around Summit Therapeutics this week
News at the entities that move Summit Therapeutics most-
Akeso StructuralJanus Henderson is backing biotech reverse mergers while dueling drug data emerges between involved companies.Moves Summit Therapeutics
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Summit Therapeutics
-
Europe StructuralThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves Summit Therapeutics
-
Cantor Fitzgerald Mentioned togetherAnalyst firm lowered price targets on Automatic Data Processing (ADP) stock on June 6, 2026.Moves Summit Therapeutics
-
Merck OperationalEli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.Moves Summit Therapeutics
-
AstraZeneca TransactionalAstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Moves Summit Therapeutics
Connections
The 10 strongest of 28, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Akeso Structural
Summit Therapeutics relies on Akeso's core IP and engineering expertise for the co-development and commercialization of ivonescimab.
-
FDA Structural
Summit Therapeutics is currently undergoing review by the FDA, which sets the standards for drug approval and market access.
-
AstraZeneca Transactional
AstraZeneca is actively negotiating and partnering with Summit Therapeutics regarding lung cancer drug development and licensing.
-
Revolution Medicines (United States) Operational
The companies are engaged in a clinical collaboration to evaluate drug combinations for cancer treatment.
-
Merck Operational
Summit Therapeutics and Merck are direct competitors in the pharmaceutical market, with A's drug ivonescimab being clinically pitted against Merck's Keytruda.
-
Europe Structural
Summit Therapeutics holds proprietary rights and markets drugs within the European territory.
-
Elon Musk Mentioned together
The evidence places both entities in the category of high-earning tech executives.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald analysts have provided positive ratings and commentary on Summit Therapeutics' drug data.
Show all 10 connections
-
MIaMI Shared context
Summit Therapeutics is headquartered in Miami.
-
Leerink partners Mentioned together
Evidence is insufficient to establish a relationship between Summit Therapeutics and Leerink partners.
History
Events by the month they beganSeptember 2026
1 eventJuly 2026
2 eventsJune 2026
6 events- Chinese biopharma is gaining ground, producing oncology drugs that rival established Western pharmaceuticals like those associated with Merck.
- Vertex Pharmaceuticals, Eli Lilly, and Summit Therapeutics are drugmakers with ongoing clinical trials.
- Revolution Medicines and Summit Therapeutics announced a collaboration on August 19, 2025, to evaluate combination therapies.
- Summit Therapeutics and AstraZeneca announced a partnership on July 4, 2025, to collaborate on lung cancer drug development.
- Summit Therapeutics acquired an exclusive license from Akeso for developing bispecific assets, with ivonescimab showing strong results compared to Keytruda.
- Revolution Medicines and Summit Therapeutics are collaborating to evaluate combination therapies using RAS inhibitors and ivonescimab for targeted cancer treatment.